FDA Authorizes Robot for Bladder Tumor Removal

Virtuoso Surgical's endoscopic system removes bladder tumors in one piece without incisions, with a focused U.S. launch planned for 2027.

Updated on Nov. 10, 2026 in Cancer

Bold flat-color vector illustration of a slender endoscope ending in two tiny articulated robotic arms against a cream background.
Virtuoso Surgical's robotic endoscopy system, which removes bladder tumors in one piece through the urethra without incisions, received FDA de novo authorization. AI Illustration. Upload story photo >

Live Poll

Would you feel more confident in a bladder tumor surgery done by a robot?

The FDA granted de novo authorization to Virtuoso Surgical's robotic system for endoscopic surgery to remove bladder tumors, the company announced Tuesday. The device is the first in a new FDA classification for electromechanical surgical systems used in endoluminal procedures.

Why it matters

The system is designed to remove bladder tumors in one piece rather than fragments, which can preserve tissue and information pathologists need to diagnose bladder cancer and plan treatment. It offers an incision-free alternative to conventional resection for patients with bladder cancer.

In the first 20 patients of the VIABLE study, detrusor muscle was present in 94% of removed lesions, above the 60% study goal and the roughly 70% median reported for conventional resection. The sample is small and longer-term outcomes have not been reported.

The players

Virtuoso Surgical

Virtuoso Surgical is the Nashville, Tennessee-based company that developed the robotic endoscopic system and is seeking to commercialize it in the United States.

Dr. Sam Chang

Dr. Sam Chang is a urologist who is a paid consultant to Virtuoso Surgical and is linked to the VIABLE study results.

The details

Virtuoso's system places two miniaturized robotic arms at the tip of a standard-sized endoscope that operates through the urethra without incisions. The robot received breakthrough device designation from the FDA in September 2025 and is the first device in the new classification.

Timeline

  1. September 2025: FDA grants the robot breakthrough device designation.

  2. November 10, 2026: FDA de novo authorization is announced by the company on Tuesday.

  3. 2027: Planned focused U.S. launch at leading urology centers.

Medical Landscape

The system departs from conventional transurethral resection of bladder tumors, which typically removes tumors in fragments, by enabling en bloc removal through the urethra. Virtuoso is also exploring the platform in other specialties that use rigid endoscopes.

Patients with bladder tumors may eventually have an incision-free option that removes tumors in one piece, which can aid diagnosis and treatment planning. Availability will initially be limited to leading urology centers beginning in 2027.

The takeaway

Patients facing bladder cancer diagnosis can ask their urologist whether en bloc tumor removal is an option at their treating center. Early-stage device results are promising but still limited to small cohorts.

What happens next

Virtuoso plans a focused U.S. launch at leading urology centers in 2027.

Further reading

Explore more in Cancer coverage for context on bladder cancer treatment advances.

Live Poll

Would you feel more confident in a bladder tumor surgery done by a robot?